ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet12978ometendo-12978Research ArticleОБЗОРREVIEWВлияние хирургического лечения ожирения на течение неалкогольной жировой болезни печениInfluence of surgical treatment of obesity on the course of nonalcoholic fatty liver diseasehttps://orcid.org/0000-0002-2948-5019ПушкареваА. С.PushkarevaA. S.

Пушкарева Анастасия Станиславовна

eLibrary SPIN: 1996-5308

117036, Москва, ул. Дм. Ульянова, д. 11

Anastasiya S. Pushkareva, MD

11 Dm. Ulyanova street, 117036 Moscow

eLibrary SPIN: 1996-5308

npushkareva96@mail.ruhttps://orcid.org/0000-0001-8077-9381МазуринаН. В.MazurinaN. V.

Мазурина Наталия Валентиновна, к.м.н.

Researcher ID: S-2312-2016eLibrary SPIN: 9067-3062

Москва

Natalya V. Mazurina, MD, PhD

Moscow

eLibrary SPIN: 9067-3062

natalyamazurina@mail.ruhttps://orcid.org/0000-0002-6624-2374КомшиловаК. А.KomshilovaK. A.

Комшилова Ксения Андреевна, к.м.н.

eLibrary SPIN: 2880-9644

Москва

Kseniya A. Komshilova, MD, PhD

Moscow

eLibrary SPIN: 2880-9644

kom-ksusha@rambler.ruhttps://orcid.org/0000-0002-6220-4397ЕршоваЕ. В.ErshovaE. V.

Ершова Екатерина Владимировна, к.м.н.

eLibrary SPIN: 6728-3764

Москва

Ekaterina V. Ershova, MD, PhD

Moscow

eLibrary SPIN: 6728-3764

yu99pol06@rambler.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202327072023203237244Copyright © Пушкарева А.С., Мазурина Н.В., Комшилова К.А., Ершова Е.В., 20232023Пушкарева А.С., Мазурина Н.В., Комшилова К.А., Ершова Е.В.Pushkareva A.S., Mazurina N.V., Komshilova K.A., Ershova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/12978

Неалкогольная жировая болезнь печени (НАЖБП) представляет собой заболевание печени с характерным накоплением жировых включений в гепатоцитах и включает спектр поражений печени от стеатоза до цирроза. Ввиду роста заболеваемости ожирением и связанной с ним НАЖБП проводится поиск оптимальных методов лечения. Авторами проведен анализ опубликованных клинических исследований по влиянию бариатрических операций на морфологические изменения в печени. Поиск литературы проводился по ключевым словам «неалкогольная жировая болезнь печени», «ожирение», «бариатрическая хирургия» в базах Pubmed и еLibrary.ru за период с 1990 по 2022 гг. Рассмотрены как положительные эффекты хирургического лечения ожирения в виде уменьшения степеней стеатоза и стеатогепатита, так и неблагоприятные последствия в виде усугубления цирроза у пациентов после перенесенной операции. Несмотря на очевидную эффективность бариатрических операций в отношении компонентов метаболического синдрома, связанных с ожирением, до сих пор не существует однозначного мнения об их эффективности в отношении НАЖБП.

Non-alcoholic fatty liver disease (NAFLD) is a liver disease with a characteristic accumulation of fatty inclusions in hepatocytes and includes a spectrum of liver lesions from steatosis to cirrhosis. In view of the increasing incidence of obesity and associated NAFLD, a search is underway for optimal treatments. The authors analyzed published clinical studies on the effect of bariatric surgery on morphological changes in the liver. The literature was searched for the keywords «non-alcoholic fatty liver disease», «obesity», «bariatric surgery» in Pubmed databases and еLibrary.ru for the period from 1990 to 2022 . Both the positive effects of surgical treatment of obesity in the form of a decrease in steatosis, steatohepatitis of the liver, and adverse effects in the form of aggravation of cirrhosis in patients after surgery are considered. Despite the obvious effectiveness of bariatric surgery in relation to the components of the metabolic syndrome associated with obesity, there is still no unambiguous opinion about their effectiveness in relation to NAFLD.

неалкогольная жировая болезнь печениожирениебариатрическая операция.non-alcoholic fatty liver diseaseobesitybariatric surgeryReferencesЛазебник Л.Б., Голованова Е.В., Туркина С.В., и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия // Экспериментальная и клиническая гастроэнтерология. — 2021. — Т. 1. — №1. — С. 4-52. doi: https://doi.org/10.31146/1682-8658-ecg-185-1-4-52Lazebnik LB, Golovanova EV, Turkina SV, et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.). doi: https://doi.org/10.31146/1682-8658-ecg-185-1-4-52Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: https://doi.org/10.1002/hep.28431Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: https://doi.org/10.1002/hep.28431Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11(1):1-16. doi: https://doi.org/10.1016/j.cld.2007.02.009Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11(1):1-16. doi: https://doi.org/10.1016/j.cld.2007.02.009Leite NC, Salles GF, Araujo ALE, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113-119. doi: https://doi.org/10.1111/j.1478-3231.2008.01718.xLeite NC, Salles GF, Araujo ALE, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113-119. doi: https://doi.org/10.1111/j.1478-3231.2008.01718.xAssy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-1934. doi: https://doi.org/10.1023/a:1005661516165Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-1934. doi: https://doi.org/10.1023/a:1005661516165Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. doi: https://doi.org/10.1002/hep.25762Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. doi: https://doi.org/10.1002/hep.25762Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого много центрового проспективного исследования DIREGL 019030) // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2014. — Т.24. — №4. — С.32-38.Drapkina OM, Ivashkin VT. Jepidemiologicheskie osobennosti nealkogol’noj zhirovoj bolezni pecheni v Rossii (rezul’taty otkrytogo mnogo centrovogo prospektivnogo issledovanija DIREGL 019030). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(4):32-38. (In Russ.).Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes, Obes Metab. 2015;17(11):1021-1032. doi: https://doi.org/10.1111/dom.12502Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes, Obes Metab. 2015;17(11):1021-1032. doi: https://doi.org/10.1111/dom.12502VanWagner LB, Rinella ME. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Reports. 2016;15(2):75-85. doi: https://doi.org/10.1007/s11901-016-0295-9VanWagner LB, Rinella ME. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Reports. 2016;15(2):75-85. doi: https://doi.org/10.1007/s11901-016-0295-9Sasaki A, Nitta H, Otsuka K, et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne). 2014;5(2):75-85. doi: https://doi.org/10.3389/fendo.2014.00164Sasaki A, Nitta H, Otsuka K, et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne). 2014;5(2):75-85. doi: https://doi.org/10.3389/fendo.2014.00164Subichin M, Clanton J, Makuszewski M, et al. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11(1):137-141. doi: https://doi.org/10.1016/j.soard.2014.06.015Subichin M, Clanton J, Makuszewski M, et al. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11(1):137-141. doi: https://doi.org/10.1016/j.soard.2014.06.015Festi D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5(1):27-42. doi: https://doi.org/10.1111/j.1467-789x.2004.00126.xFesti D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5(1):27-42. doi: https://doi.org/10.1111/j.1467-789x.2004.00126.xPetersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci. 2006;103(48):18273-18277. doi: https://doi.org/10.1073/pnas.0608537103Petersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci. 2006;103(48):18273-18277. doi: https://doi.org/10.1073/pnas.0608537103Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362(12):1082-1089. doi: https://doi.org/10.1056/NEJMoa0907295Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362(12):1082-1089. doi: https://doi.org/10.1056/NEJMoa0907295Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis. 2009;41(9):615-625. doi: https://doi.org/10.1016/j.dld.2009.01.004Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis. 2009;41(9):615-625. doi: https://doi.org/10.1016/j.dld.2009.01.004Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-1465. doi: https://doi.org/10.1038/ng.257Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-1465. doi: https://doi.org/10.1038/ng.257Мишина Е.Е., Майоров А.Ю., Богомолов П.О., и др. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистености? // Сахарный диабет. — 2017. — Т. 20. — №5. — С. 335-342. doi: https://doi.org/10.14341/DM9372Mishina EE, Mayorov AY, Bogomolov PO, et al. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes mellitus. 2017;20(5):335-343. (In Russ.). doi: https://doi.org/10.14341/DM9372Prashanth M, Ganesh HK, Vima MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;(57):205-210.Prashanth M, Ganesh HK, Vima MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;(57):205-210.Fan N, Zhang L, Xia Z, et al. Sex-specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Res. 2016;2016:1-6. doi: https://doi.org/10.1155/2016/3805372Fan N, Zhang L, Xia Z, et al. Sex-specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Res. 2016;2016:1-6. doi: https://doi.org/10.1155/2016/3805372Киселева Е.В., Демидова Т.Ю. Неалкогольная жировая болезнь печени и сахарный диабет 2 типа: проблема сопряженности и этапности развития // Ожирение и метаболизм. — 2021. — Т. 18. — №3. — C. 313-319. doi: https://doi.org/10.14341/omet12758Kiseleva EV, Demidova TY. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjunction and phasing. Obesity and metabolism. 2021;18(3):313-319. (In Russ.). doi: https://doi.org/10.14341/omet12758Драпкина О.М., Корнеева О.Н. Континуум неалкогольной жировой болезни печени: от стеатоза печени до сердечно-сосудистого риска // Рациональная фармакотерапия в кардиологии. — 2016. — Т. 12. — №4. — С. 424-429. doi: https://doi.org/10.20996/1819-6446-2016-12-4-424-429Drapkina OM, Korneeva ON. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Ration Pharmacother Cardiol. 2016;12(4):424-429. (In Russ.). doi: https://doi.org/10.20996/1819-6446-2016-12-4-424-429Wu K-T, Kuo P-L, Su S-B, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016;10(2):420-425.e1. doi: https://doi.org/10.1016/j.jacl.2015.12.026Wu K-T, Kuo P-L, Su S-B, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016;10(2):420-425.e1. doi: https://doi.org/10.1016/j.jacl.2015.12.026Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820-826. doi: https://doi.org/10.1002/hep.20410Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820-826. doi: https://doi.org/10.1002/hep.20410Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005;33(2):72-76. doi: https://doi.org/10.1016/j.hepres.2005.09.007Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005;33(2):72-76. doi: https://doi.org/10.1016/j.hepres.2005.09.007Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129(1):113-121. doi: https://doi.org/10.1053/j.gastro.2005.04.014Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129(1):113-121. doi: https://doi.org/10.1053/j.gastro.2005.04.014Miyaaki H, Ichikawa T, Nakao K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int. 2007;28(4):519-524. doi: https://doi.org/10.1111/j.1478-3231.2007.01614.xMiyaaki H, Ichikawa T, Nakao K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int. 2007;28(4):519-524. doi: https://doi.org/10.1111/j.1478-3231.2007.01614.xAscha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972-1978. doi: https://doi.org/10.1002/hep.23527Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972-1978. doi: https://doi.org/10.1002/hep.23527Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(S19):89-95. doi: https://doi.org/10.1007/s00535-008-2262-xHashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(S19):89-95. doi: https://doi.org/10.1007/s00535-008-2262-xMisra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11(1):50-55. doi: https://doi.org/10.1007/s11894-009-0008-4Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11(1):50-55. doi: https://doi.org/10.1007/s11894-009-0008-4Stefan N, Kantartzis K, Häring H-U. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008;29(7):939-960. doi: https://doi.org/10.1210/er.2008-0009Stefan N, Kantartzis K, Häring H-U. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008;29(7):939-960. doi: https://doi.org/10.1210/er.2008-0009Широкова Е.Н. Неалкогольная жировая болезнь печени, гиперлипидемия и сердечно-сосудистые риски // Consilium Medicum. — 2017. — Т. 19 — (8.2. Гастроэнтерология) — С. 74-76. doi: https://doi.org/10.26442/2075-1753_19.8.2.74-76Shirokova EN. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Consilium Medicum. 2017;19(8.2. Gastroenterology):74-76. (In Russ.). doi: https://doi.org/10.26442/2075-1753_19.8.2.74-76Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53(5):1504-1514. doi: https://doi.org/10.1002/hep.24242Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53(5):1504-1514. doi: https://doi.org/10.1002/hep.24242Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: The good and the bad. Clin Nutr. 2014;33(2):186-190. doi: https://doi.org/10.1016/j.clnu.2013.11.003Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: The good and the bad. Clin Nutr. 2014;33(2):186-190. doi: https://doi.org/10.1016/j.clnu.2013.11.003Asrih M, Jornayvaz FR. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi: https://doi.org/10.1016/j.jhep.2015.11.004Asrih M, Jornayvaz FR. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi: https://doi.org/10.1016/j.jhep.2015.11.004Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi: https://doi.org/10.1002/hep.29367Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi: https://doi.org/10.1002/hep.29367Houmard JA, Tanner CJ, Slentz CA, et al. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol. 2004;96(1):101-106. doi: https://doi.org/10.1152/japplphysiol.00707.2003Houmard JA, Tanner CJ, Slentz CA, et al. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol. 2004;96(1):101-106. doi: https://doi.org/10.1152/japplphysiol.00707.2003Kopp C, Kopp H-P, Steiner S, et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res. 2003;11(8):950-956. doi: https://doi.org/10.1038/oby.2003.131Kopp C, Kopp H-P, Steiner S, et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res. 2003;11(8):950-956. doi: https://doi.org/10.1038/oby.2003.131Лызлова С.М., Фишман М.Б., Райхельсон К.Л. Потенциальное влияние бариатрических операций на течение неалкогольной болезни печени у пациентов с морбидным ожирением // Евразийский союз ученых. Медицинские науки. — 2015. — Т. 3. — №12. — С. 91-93. doi : https://doi.org/10.31618/ESU.2413-9335Lyzlova SM, Fishman MB, Rajhel’son KL. Potencial’noe vlijanie bariatricheskih operacij na techenie nealkogol’noj bolezni pecheni u pacientov s morbidnym ozhireniem. Evrazijskij sojuz uchenyh. Medicinskie nauki. 2015;3(12):91-93. (In Russ.). doi : https://doi.org/10.31618/ESU.2413-9335Buchwald H., Avidor Y., Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724. doi: https://doi.org/10.1001/jama.292.14.1724Buchwald H., Avidor Y., Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724. doi: https://doi.org/10.1001/jama.292.14.1724Корнюшин О.В., Торопова Я.Г., Неймарк А.Е., и др. Механизмы влияния бариатрических операций на течение неалкогольной жировой болезни печени // Экспериментальная и клиническая гастроэнтерология. — 2017. — Т. 146. — №10. — С. 61-73.Kornjushin OV, Toropova JaG, Nejmark AE, et al. Mehanizmy vlijanija bariatricheskih operacij na techenie nealkogol’noj zhirovoj bolezni pecheni. Experimental and Clinical Gastroenterology. 2017;146(10):61-73. (In Russ.).Ranløv I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion. 1990;47(4):208-214. doi: https://doi.org/10.1159/000200499Ranløv I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion. 1990;47(4):208-214. doi: https://doi.org/10.1159/000200499Craig CM, Liu L-F, Deacon CF, et al. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia. 2017;60(3):531-540. doi: https://doi.org/10.1007/s00125-016-4179-xCraig CM, Liu L-F, Deacon CF, et al. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia. 2017;60(3):531-540. doi: https://doi.org/10.1007/s00125-016-4179-xSteinert RE, Feinle-Bisset C, Asarian L, et al. Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1):411-463. doi: https://doi.org/10.1152/physrev.00031.2014Steinert RE, Feinle-Bisset C, Asarian L, et al. Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1):411-463. doi: https://doi.org/10.1152/physrev.00031.2014Costa Justus JF, Ligocki Campos AC, Figueroa ALC, et al. Early effect of bariatric surgery on the circadian rhythms of adipokines in morbidly obese women. Metab Syndr Relat Disord. 2016;14(1):16-22. doi: https://doi.org/10.1089/met.2015.0051Costa Justus JF, Ligocki Campos AC, Figueroa ALC, et al. Early effect of bariatric surgery on the circadian rhythms of adipokines in morbidly obese women. Metab Syndr Relat Disord. 2016;14(1):16-22. doi: https://doi.org/10.1089/met.2015.0051Корнюшин О.В., Торопова Я.Г., Берко О.М., и др. Морфологические изменения печени у крыс с моделью стеатоза печени и декомпенсированного диабета 2 типа после выполнения различных типов бариатрических операций // Экспериментальная и клиническая гастроэнтерология. — 2019. — Т. 168. — №8. — С. 72–76. doi: https://doi.org/10.31146/1682-8658-ecg-168-8-72-76Kornyushin OV, Toropova YG, Berko OM, et al. Morphological changes in the liver in rats for liver diseases and decompensated type 2 diabetes after performing various types of bariatric operations. Experimental and Clinical Gastroenterology. 2019;(8):72-76. (In Russ.). doi: https://doi.org/10.31146/1682-8658-ecg-168-8-72-76Froylich D, Corcelles R, Daigle C, et al. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12(1):127-131. doi: https://doi.org/10.1016/j.soard.2015.04.004Froylich D, Corcelles R, Daigle C, et al. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12(1):127-131. doi: https://doi.org/10.1016/j.soard.2015.04.004Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA. et al. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism. 2016;65(8):1196-1207. doi: https://doi.org/10.1016/j.metabol.2015.09.004Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA. et al. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism. 2016;65(8):1196-1207. doi: https://doi.org/10.1016/j.metabol.2015.09.004Taitano AA, Markow M, Finan JE, et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2015;19(3):429-437. doi: https://doi.org/10.1007/s11605-014-2678-yTaitano AA, Markow M, Finan JE, et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2015;19(3):429-437. doi: https://doi.org/10.1007/s11605-014-2678-yAldoheyan T, Hassanain M, Al-Mulhim A, et al. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc. 2017;31(3):1142-1147 doi: https://doi.org/10.1007/s00464-016-5082-8Aldoheyan T, Hassanain M, Al-Mulhim A, et al. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc. 2017;31(3):1142-1147 doi: https://doi.org/10.1007/s00464-016-5082-8Major P, Pędziwiatr M, Rubinkiewicz M, et al. Impact of bariatric surgery on non-alcoholic fatty liver disease. Pol Przegl Chir. 2017;89(2):1-4 doi: https://doi.org/10.5604/01.3001.0009.6003Major P, Pędziwiatr M, Rubinkiewicz M, et al. Impact of bariatric surgery on non-alcoholic fatty liver disease. Pol Przegl Chir. 2017;89(2):1-4 doi: https://doi.org/10.5604/01.3001.0009.6003Nickel F, Tapking C, Benner L, et al. Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up. Obes Surg. 2018;28(5):1342-1350. doi: https://doi.org/10.1007/s11695-017-3012-zNickel F, Tapking C, Benner L, et al. Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up. Obes Surg. 2018;28(5):1342-1350. doi: https://doi.org/10.1007/s11695-017-3012-zChaim FDM, Pascoal LB, Chaim FHM, et al. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Sci Rep. 2020;10(1):8496. doi: https://doi.org/10.1038/s41598-020-65556-2Chaim FDM, Pascoal LB, Chaim FHM, et al. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Sci Rep. 2020;10(1):8496. doi: https://doi.org/10.1038/s41598-020-65556-2Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396-1402. doi: https://doi.org/10.1016/j.cgh.2008.08.012Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396-1402. doi: https://doi.org/10.1016/j.cgh.2008.08.012Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons aft er gastric bypass. Am J Clin Pathol. 1995;104(1):23-31. doi: https://doi.org/10.1093/ajcp/104.1.23Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons aft er gastric bypass. Am J Clin Pathol. 1995;104(1):23-31. doi: https://doi.org/10.1093/ajcp/104.1.23Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135(1):48-58. doi: https://doi.org/10.1016/j.surg.2003.10.003Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135(1):48-58. doi: https://doi.org/10.1016/j.surg.2003.10.003Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg. 2006;16(5):607-611. doi: https://doi.org/10.1381/096089206776944904Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg. 2006;16(5):607-611. doi: https://doi.org/10.1381/096089206776944904Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137(2):532-540. doi: https://doi.org/10.1053/j.gastro.2009.04.052Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137(2):532-540. doi: https://doi.org/10.1053/j.gastro.2009.04.052Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010;6(12):1396-1402. doi: https://doi.org/10.1002/14651858.CD007340.pub2Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010;6(12):1396-1402. doi: https://doi.org/10.1002/14651858.CD007340.pub2

The authors declare that there are no conflicts of interest present.